Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anticoagulant regimen for non-valvular atrial fibrillation in the elderly and frail population.

The American journal of cardiology·2026

Same author

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026

Same author

Long-term prognostic impact of optical coherence tomography detected plaque rupture in nonculprit coronary segments.

Atherosclerosis·2026

Same author

Left Atrial Appendage Occlusion in the Era of Minimalist Approaches: Anesthesia and Imaging Considerations.

Journal of clinical medicine·2026

Same author

First scan, then treat: 10 years of the SCOT-HEART study.

European heart journal supplements : journal of the European Society of Cardiology·2026

Same author

Coronary artery anomalies: contemporary approaches to risk stratification and management.

European heart journal supplements : journal of the European Society of Cardiology·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study.

Laura Gatto^1,2, Maria Pia Di Bitonto³, Lorenzo Scalia⁴

¹Cardiovascular Sciences Department, San Giovanni Addolorata Hospital, Rome, Italy.

European Heart Journal Supplements : Journal of the European Society of Cardiology

|May 8, 2026

Summary

Evolocumab significantly lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular event risk in both primary and secondary prevention patients. This PCSK9 inhibitor offers a safe and effective option for those not reaching LDL-C goals with statins alone.

Keywords:

Cardiovascular prevention Evolocumab Low-density lipoprotein cholesterol Proprotein convertase subtilisin/kexin type 9 inhibitors

Related Experiment Videos

Last Updated: May 9, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Area of Science:

Cardiology
Pharmacology
Preventive Medicine

Background:

Elevated low-density lipoprotein cholesterol (LDL-C) is a primary driver of atherosclerotic cardiovascular disease.
Many high-risk patients do not achieve target LDL-C levels with statin therapy alone, necessitating additional treatments.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, like evolocumab, effectively reduce LDL-C and cardiovascular risk.

Purpose of the Study:

To evaluate the efficacy and safety of evolocumab in primary prevention for high cardiovascular risk patients.
To assess the role of evolocumab in reducing major adverse cardiovascular events in a broad patient population.

Main Methods:

The VESALIUS-CV trial investigated evolocumab's impact on LDL-C reduction and cardiovascular outcomes.
A placebo-controlled study design was employed to assess the safety and efficacy profile.
Participants included high cardiovascular risk individuals without prior major cardiovascular events.

Main Results:

Evolocumab demonstrated significant and sustained LDL-C reduction (approximately 60%).
The trial showed a significant reduction in the risk of first cardiovascular events, including myocardial infarction and revascularization.
Evolocumab exhibited a safety profile comparable to placebo.

Conclusions:

Evolocumab is an effective and safe strategy for cardiovascular risk reduction in both primary and secondary prevention.
The findings support the use of evolocumab for patients across the cardiovascular risk spectrum.
Personalized therapeutic strategies based on global cardiovascular risk are crucial.